Cardiovascular Drugs and Therapy

, Volume 24, Issue 5–6, pp 373–378 | Cite as

Efficacy of Simvastatin in Reducing Aortic Dilatation in Mouse Models of Abdominal Aortic Aneurysm

  • Jonathan GolledgeEmail author
  • Bradford Cullen
  • Corey Moran
  • Catherine Rush



Currently there is no effective drug therapy for abdominal aortic aneurysm (AAA). The aim of this study was to assess the ability of simvastatin to inhibit aortic dilatation in two mouse models.


AAAs were induced in two mice strains predisposed to atherosclerosis. Firstly, 11 weeks old male apolipoprotein E deficient (ApoE−/−) mice were given vehicle control (n = 27) or simvastatin (50 mg/kg/d, n = 27) prior to being infused with angiotensin II (1 μg/kg/min) subcutaneously for 4 weeks. Secondly, 9 weeks old male low-density lipoprotein receptor deficient (LDLR−/−) mice were fed a high fat diet, then given vehicle control (n = 17) or simvastatin (50 mg/kg/d, n = 18) and from 14 to 18 weeks of age infused with angiotensin II. Subsequently aortas were harvested, maximum suprarenal aortic diameter measured, aortic arch atheroma assessed by sudan IV staining and blood extracted to measure serum lipids. In the LDLR−/− mice the suprarenal aortic diameter was also measured by ultrasound prior to aortic harvesting.


In ApoE−/− mice suprarenal aortic diameters were modestly smaller in animals receiving simvastatin without significant change despite reduction in macrophage infiltration. Aortic arch atheroma was substantially reduced in LDLR−/− mice receiving simvastatin with borderline significant reduction in suprarenal aortic diameters. Simvastatin did not favourably modify serum lipids in either mouse model.


In this study involving two mouse models of AAA, simvastatin had limited efficacy in restricting aortic dilatation but substantial ability to reduce atheroma progression.

Key words

Aorta Aneurysm Mouse model Simvastatin Atherosclerosis 



Grants from the National Health and Medical Research Council (project grant 379600 and 540404) supported this work. JG is supported by Practitioner Fellowship from the National Health and Medical Research Council, Australia (431503).


  1. 1.
    Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605–13.PubMedCrossRefGoogle Scholar
  2. 2.
    Propanolol Aneurysm Trial Investigators. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg. 2002;35:72–9.Google Scholar
  3. 3.
    Lindholt JS, Henneberg EW, Juul S, Fasting H. Impaired results of a randomised double blinded clinical trial of propranolol versus placebo on the expansion rate of small abdominal aortic aneurysms. Int Angiol. 1999;18:52–7.PubMedGoogle Scholar
  4. 4.
    Wilmink AB, Hubbard CS, Day NE, Quick CR. Effect of propanolol on the expansion of abdominal aortic aneurysms: a randomised study. Br J Surg. 2000;87:499.CrossRefGoogle Scholar
  5. 5.
    Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg. 2001;34:606–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Vammen S, Lindholt JS, Ostergaard L, Fasting H, Henneberg EW. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg. 2001;88:1066–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Steinmetz EF, Buckley C, Shames ML, Ennis TL, Vanvickle-Chavez SJ, Mao D, et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005;241:92–101.PubMedGoogle Scholar
  8. 8.
    Zhang Y, Naggar JC, Welzig CM, Beasley D, Moulton KS, Park HJ, et al. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol. 2009;29:1764–71.PubMedCrossRefGoogle Scholar
  9. 9.
    Kajimoto K, Miyauchi K, Kasai T, Shimada K, Kojima Y, Shimada A, et al. Short-term 20-mg atorvastatin therapy reduces key inflammatory factors including c-Jun N-terminal kinase and dendritic cells and matrix metalloproteinase expression in human abdominal aortic aneurysmal wall. Atherosclerosis 2009;206:505–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Nakamura K, Sasaki T, Cheng XW, Iguchi A, Sato K, Kuzuya M. Statin prevents plaque disruption in apoE-knockout mouse model through pleiotropic effect on acute inflammation. Atherosclerosis 2009;206:355–61.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen Z, Fukutomi T, Zago AC, Ehlers R, Detmers PA, Wright SD, et al. Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids. Circulation 2002;106:20–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, et al. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. Immunol 2006;177:3028–34.Google Scholar
  13. 13.
    Bisgaier CL, Essenburg AD, Auerbach BJ, Pape ME, Sekerke CS, Gee A, et al. Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res. 1997;38:2502–15.PubMedGoogle Scholar
  14. 14.
    Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, et al. Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway. Circ Res. 2006;98:361–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2003;23:483–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q, et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and pro6teolysis. Circulation 2005;111:2219–26.PubMedCrossRefGoogle Scholar
  17. 17.
    Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005;11:1330–8.PubMedCrossRefGoogle Scholar
  18. 18.
    King VL, Trivedi D, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol. 2006;26:1137–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Martin-McNulty B, Tham DM, da Cunha V, Ho JJ, Wilson DW, Rutledge JC, et al. 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1627–32.PubMedCrossRefGoogle Scholar
  20. 20.
    Rush C, Nyara M, Moxon JV, Trollope A, Cullen B, Golledge J. Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm. BMC Genomics. 2009;10:298.PubMedCrossRefGoogle Scholar
  21. 21.
    Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, et al. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis 2010;210:88–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Moran CS, Cullen B, Campbell JH, Golledge J. Interaction between angiotensin II, osteoprotegerin, and peroxisome proliferator-activated receptor-gamma in abdominal aortic aneurysm. J Vasc Res. 2009;46:209–17.PubMedCrossRefGoogle Scholar
  23. 23.
    Cassis LA, Rateri DL, Lu H, Daugherty A. Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol. 2007;27:380–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Bea F, Blessing E, Shelley MI, Shultz JM, Rosenfeld ME. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003;167:187–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Schouten O, van Laanen JH, Boersma E, Vidakovic R, Feringa HH, Dunkelgrün M, et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006;32:21–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Mosorin M, Niemelä E, Heikkinen J, Lahtinen J, Tiozzo V, Satta J, et al. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg. 2008;7:578–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Ferguson C, Clancy P, Bourke B, Walker P, Dear A, Buckenham T, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 2010;159:307–13.PubMedCrossRefGoogle Scholar
  28. 28.
    Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Tromsø Study, 1994–2001. Circulation 2009;119:2202–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Jonathan Golledge
    • 1
    Email author
  • Bradford Cullen
    • 1
  • Corey Moran
    • 1
  • Catherine Rush
    • 1
  1. 1.The Vascular Biology Unit, Department of Surgery, School of MedicineJames Cook UniversityTownsvilleAustralia

Personalised recommendations